LifeStance Health Confirms Closing of Secondary Offering and 7M Share Repurchase
LFST sits 91% above its 52-week low of $3.74 on elevated volume (2.3× avg).
Summary
LifeStance Health Group announced the closing of a secondary offering where selling stockholders sold 25 million shares, with the company simultaneously repurchasing 7 million shares at $7.01 per share.
Key Events · Financing and Capital Events · LFST
-
Secondary Offering Closed
Selling stockholders completed the sale of 25,000,000 shares of common stock at $7.01 per share. The company did not receive any proceeds from this sale.
-
Company Repurchases Shares
LifeStance Health Group repurchased 7,000,000 shares from the underwriter at $7.01 per share, totaling $49.07 million. This repurchase is part of the previously announced $100 million share repurchase program.
Analysis · LFST · Industrial Applications And Services
This 8-K confirms the completion of the previously announced secondary offering and the company's share repurchase. While selling stockholders disposed of a substantial 25 million shares, representing a significant portion of the company's market capitalization, LifeStance Health Group's concurrent repurchase of 7 million shares at the offering price mitigates the dilutive impact and signals management's confidence or intent to support the stock. This transaction follows the company's recent announcement of strong Q4 and full-year 2025 results and a $100 million share repurchase program.
How filings like this one have moved
In the 30 days to Sep 12, 2026, 29.6% of the 1872 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.19%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LFST was trading at $7.14 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $2.8B. The 52-week trading range was $3.74 to $8.30. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.